Silvia Cristina Mărginean Claudia Ogrean Ramona Orăștean Editors 2017 International Economics Conference in Sibiu (IECS)
![Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation](https://www.ahajournals.org/cms/asset/2514dc29-80c9-4360-9eba-1d2aca429823/54fig01.jpeg)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation
![Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation](https://www.ahajournals.org/cms/asset/720e0855-ec36-423d-a339-b4807e64de9a/54fig03.jpeg)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation
![Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation](https://www.ahajournals.org/cms/asset/a1bc1993-9784-42e4-a1be-45c14aa4ce7d/54fig02.jpeg)